Addendum

Lenvatinib (hepatocellular carcinoma) - Addendum to Commission A18-57

Report documents

Indication:

Adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy

Result of dossier assessment:

Added benefit still not proven for both research questions after analysis of further data

2019-03-22 A G-BA decision was published.

Project no.: A19-15
Commission: Commission awarded on 12.03.2019 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note: If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.